Cargando…

The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR

OBJECTIVE: The awareness, time in therapeutic range (TTR), and safety of warfarin therapy were investigated in the adult Turkish population. METHODS: This multicenter prospective study includes 4987 patients using warfarin and involved regular international normalized ratio (INR) monitoring between...

Descripción completa

Detalles Bibliográficos
Autores principales: Çelik, Ahmet, İzci, Servet, Kobat, Mehmet Ali, Ateş, Ahmet Hakan, Çakmak, Abdülkadir, Çakıllı, Yasin, Yılmaz, Mehmet Birhan, Zoghi, Mehdi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kare Publishing 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368516/
https://www.ncbi.nlm.nih.gov/pubmed/27004711
http://dx.doi.org/10.5152/AnatolJCardiol.2015.6474
_version_ 1782517947312373760
author Çelik, Ahmet
İzci, Servet
Kobat, Mehmet Ali
Ateş, Ahmet Hakan
Çakmak, Abdülkadir
Çakıllı, Yasin
Yılmaz, Mehmet Birhan
Zoghi, Mehdi
author_facet Çelik, Ahmet
İzci, Servet
Kobat, Mehmet Ali
Ateş, Ahmet Hakan
Çakmak, Abdülkadir
Çakıllı, Yasin
Yılmaz, Mehmet Birhan
Zoghi, Mehdi
author_sort Çelik, Ahmet
collection PubMed
description OBJECTIVE: The awareness, time in therapeutic range (TTR), and safety of warfarin therapy were investigated in the adult Turkish population. METHODS: This multicenter prospective study includes 4987 patients using warfarin and involved regular international normalized ratio (INR) monitoring between January 1, 2014 and December 31, 2014. TTR was calculated according to F.R. Roosendaal’s algorithm. Awareness was evaluated based on the patients’ knowledge of warfarin’s affect and food–drug interactions. RESULTS: The mean TTR of patients was 49.52±22.93%. The patients with hypertension (55.3%), coronary artery disease (23.2%), congestive heart failure (24.5%), or smoking habit (20.8%) had significantly lower TTR levels than the others. Of the total number of patients, 42.6% had a mechanical valve, 38.4% had non-valvular atrial fibrillation (AF), and 19% had other indications for warfarin. Patients with other indications had lower TTR levels than those with mechanical valve and non-valvular AF (p=0.018). Warfarin awareness decreased in higher age groups. The knowledge of warfarin’s food–drug interactions was 55%. People with higher warfarin awareness had higher TTR levels. Patients with ≤8 INR monitoring/year had lower TTR levels (46.4±25.3 vs. 51.1±21.3, respectively, p<0.001) and lower awareness (44.6% vs. 60.6%, p<0.001) than patients with ≥8 INR monitoring/year. In this study, 20.1% of the patients had a bleeding event (major bleeding 15.8%, minor bleeding 84.2%) within a year. CONCLUSION: Both the mean TTR ratios and awareness of the Turkish population on warfarin therapy were found to be low. It was thought that low TTR levels of the Turkish population may be caused by the low awareness of warfarin, warfarin’s food–drug interactions, and high rates of concomitant diseases. (Anatol J Cardiol 2016; 16: 595-600)
format Online
Article
Text
id pubmed-5368516
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Kare Publishing
record_format MEDLINE/PubMed
spelling pubmed-53685162017-06-28 The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR Çelik, Ahmet İzci, Servet Kobat, Mehmet Ali Ateş, Ahmet Hakan Çakmak, Abdülkadir Çakıllı, Yasin Yılmaz, Mehmet Birhan Zoghi, Mehdi Anatol J Cardiol Original Investigation OBJECTIVE: The awareness, time in therapeutic range (TTR), and safety of warfarin therapy were investigated in the adult Turkish population. METHODS: This multicenter prospective study includes 4987 patients using warfarin and involved regular international normalized ratio (INR) monitoring between January 1, 2014 and December 31, 2014. TTR was calculated according to F.R. Roosendaal’s algorithm. Awareness was evaluated based on the patients’ knowledge of warfarin’s affect and food–drug interactions. RESULTS: The mean TTR of patients was 49.52±22.93%. The patients with hypertension (55.3%), coronary artery disease (23.2%), congestive heart failure (24.5%), or smoking habit (20.8%) had significantly lower TTR levels than the others. Of the total number of patients, 42.6% had a mechanical valve, 38.4% had non-valvular atrial fibrillation (AF), and 19% had other indications for warfarin. Patients with other indications had lower TTR levels than those with mechanical valve and non-valvular AF (p=0.018). Warfarin awareness decreased in higher age groups. The knowledge of warfarin’s food–drug interactions was 55%. People with higher warfarin awareness had higher TTR levels. Patients with ≤8 INR monitoring/year had lower TTR levels (46.4±25.3 vs. 51.1±21.3, respectively, p<0.001) and lower awareness (44.6% vs. 60.6%, p<0.001) than patients with ≥8 INR monitoring/year. In this study, 20.1% of the patients had a bleeding event (major bleeding 15.8%, minor bleeding 84.2%) within a year. CONCLUSION: Both the mean TTR ratios and awareness of the Turkish population on warfarin therapy were found to be low. It was thought that low TTR levels of the Turkish population may be caused by the low awareness of warfarin, warfarin’s food–drug interactions, and high rates of concomitant diseases. (Anatol J Cardiol 2016; 16: 595-600) Kare Publishing 2016-08 2015-11-19 /pmc/articles/PMC5368516/ /pubmed/27004711 http://dx.doi.org/10.5152/AnatolJCardiol.2015.6474 Text en Copyright © 2016 Turkish Society of Cardiology http://creativecommons.org/licenses/by-nc-sa/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
spellingShingle Original Investigation
Çelik, Ahmet
İzci, Servet
Kobat, Mehmet Ali
Ateş, Ahmet Hakan
Çakmak, Abdülkadir
Çakıllı, Yasin
Yılmaz, Mehmet Birhan
Zoghi, Mehdi
The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR
title The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR
title_full The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR
title_fullStr The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR
title_full_unstemmed The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR
title_short The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR
title_sort awareness, efficacy, safety, and time in therapeutic range of warfarin in the turkish population: warfarin-tr
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368516/
https://www.ncbi.nlm.nih.gov/pubmed/27004711
http://dx.doi.org/10.5152/AnatolJCardiol.2015.6474
work_keys_str_mv AT celikahmet theawarenessefficacysafetyandtimeintherapeuticrangeofwarfarinintheturkishpopulationwarfarintr
AT izciservet theawarenessefficacysafetyandtimeintherapeuticrangeofwarfarinintheturkishpopulationwarfarintr
AT kobatmehmetali theawarenessefficacysafetyandtimeintherapeuticrangeofwarfarinintheturkishpopulationwarfarintr
AT atesahmethakan theawarenessefficacysafetyandtimeintherapeuticrangeofwarfarinintheturkishpopulationwarfarintr
AT cakmakabdulkadir theawarenessefficacysafetyandtimeintherapeuticrangeofwarfarinintheturkishpopulationwarfarintr
AT cakıllıyasin theawarenessefficacysafetyandtimeintherapeuticrangeofwarfarinintheturkishpopulationwarfarintr
AT yılmazmehmetbirhan theawarenessefficacysafetyandtimeintherapeuticrangeofwarfarinintheturkishpopulationwarfarintr
AT zoghimehdi theawarenessefficacysafetyandtimeintherapeuticrangeofwarfarinintheturkishpopulationwarfarintr
AT theawarenessefficacysafetyandtimeintherapeuticrangeofwarfarinintheturkishpopulationwarfarintr
AT celikahmet awarenessefficacysafetyandtimeintherapeuticrangeofwarfarinintheturkishpopulationwarfarintr
AT izciservet awarenessefficacysafetyandtimeintherapeuticrangeofwarfarinintheturkishpopulationwarfarintr
AT kobatmehmetali awarenessefficacysafetyandtimeintherapeuticrangeofwarfarinintheturkishpopulationwarfarintr
AT atesahmethakan awarenessefficacysafetyandtimeintherapeuticrangeofwarfarinintheturkishpopulationwarfarintr
AT cakmakabdulkadir awarenessefficacysafetyandtimeintherapeuticrangeofwarfarinintheturkishpopulationwarfarintr
AT cakıllıyasin awarenessefficacysafetyandtimeintherapeuticrangeofwarfarinintheturkishpopulationwarfarintr
AT yılmazmehmetbirhan awarenessefficacysafetyandtimeintherapeuticrangeofwarfarinintheturkishpopulationwarfarintr
AT zoghimehdi awarenessefficacysafetyandtimeintherapeuticrangeofwarfarinintheturkishpopulationwarfarintr
AT awarenessefficacysafetyandtimeintherapeuticrangeofwarfarinintheturkishpopulationwarfarintr